Eli Lilly reported a 47.7% revenue increase to $22.97 billion in Q2 2026, surpassing expectations and raising its full-year revenue guidance to $85-$87 billion. The company’s stock trades near $1,185 with a 24/7 Wall St. price target of $1,401, suggesting an 18% upside. Key drivers include strong sales of GLP-1 drugs like Mounjaro and Zepbound, FDA approval of Onswik insulin, and promising retatrutide trial results. While competition and price declines pose risks, Lilly's rapid growth and pipeline advancements position it as a potential $2 trillion drugmaker in the coming years.
Eli Lilly's market cap on Pluang reached $1.02 trillion as of Oct 02, 2026 20:11 WIB, highlighting its stature near the $2 trillion mark discussed in the article. The stock price stood at USD 1,151.75 with a minimal 1-day change of +0.03%, showing stable investor interest despite the article's noted price target of $1,401. Pluang data also reveals a balanced order activity with 52% Sell and 48% Buy, reflecting a cautious but engaged market for Eli Lilly shares.
Eli Lilly announced promising mid-stage trial results for EloraTZP, a new obesity drug that led to up to 23.3% weight loss in overweight or obese type 2 diabetes patients after 48 weeks, outperforming Novo Nordisk's tirzepatide alone. The drug also s...
Foghorn Therapeutics saw its price target cut from $12 to $5 after it and Eli Lilly decided not to advance key cancer drug programs. The companies will not continue development of FHD-909 or a selective SMARCA2 degrader, ending their collaboration. F...
Eli Lilly's Foundayo (orforglipron) showed in post-hoc analyses of the ATTAIN-1 trial a significant reduction in predicted 10-year risks of type 2 diabetes and cardiovascular disease among adults with obesity or overweight with related health issues....
The Phase 3 ACHIEVE-4 trial found that Foundayo (orforglipron) reduced the risk of major cardiovascular events by 16% and cardiovascular death by 53% compared to insulin glargine in adults with type 2 diabetes and obesity. It also improved blood suga...
EBGLYSS (lebrikizumab-lbkz) monotherapy achieved its primary endpoint in the Phase 3b ADtouch trial, with over half of patients showing clear or almost clear skin on hands and feet by Week 16. The treatment also provided significant itch and pain rel...
